Patents by Inventor Paul Leslie Ornstein

Paul Leslie Ornstein has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Amide, carbamate, and urea derivatives
    Publication number: 20040097499
    Abstract: The present invention provides certain amide, carbamate and urea derivatives useful for potentiating glutamate receptor function in a mammal and therefore, useful for treating a wide variety of conditions, such as psychiatric and neurological disorders.
    Type: Application
    Filed: July 3, 2003
    Publication date: May 20, 2004
    Inventors: MacKlin Brian Arnold, David Michael Bender, Thomas John Bleisch, Winton Dennis Jones, Paul Leslie Ornstein, Hamid H. Zarrinmayeh, Dennis Michael Zimmerman
  • Melanocortin receptor agonists
    Publication number: 20040092507
    Abstract: The present invention relates to melanocortin receptor agonists of formula (I), which is useful in the treatment of obesity, diabetes and male and/or female sexual dysfunction.
    Type: Application
    Filed: July 11, 2003
    Publication date: May 13, 2004
    Inventors: Christopher Kelly Biggers, Karin Briner, Christopher William Doecke, Matthew Joseph Fisher, Larry Wayne Hertel, Vincent Mancuso, Michael John Martinelli, John Philip Mayer, Paul Leslie Ornstein, Timothy Ivo Richardson, Jikesh Arvind Shah, Qing Shi, Zhipei Wu, Chaoyu Xie
  • Sulfonamide derivatives
    Patent number: 6720357
    Abstract: The present invention relates to a compound of formula (Ia) or a pharmaceutically acceptable salt thereof which is useful for the treatment of conditions associated with glutamate hypofunction, such as psychiatric and neurological disorders.
    Type: Grant
    Filed: October 17, 2002
    Date of Patent: April 13, 2004
    Assignee: Eli Lilly and Company
    Inventors: Paul Leslie Ornstein, Hamideh Zarrinmayeh, Dennis Michael Zimmerman
  • Excitatory amino acid receptor antagonists
    Publication number: 20040063749
    Abstract: The present invention provides compounds of Formula I or Formula II, or the pharmaceutically acceptable salts or prodrugs thereof, pharmaceutical compositions comprising compounds or Formula I or Formula II, and methods for treating neurological disorders and neurodegenerative diseases, particularly migraine.
    Type: Application
    Filed: June 25, 2003
    Publication date: April 1, 2004
    Inventors: Thomas John Bleisch, Sandra Ann Filla, Paul Leslie Ornstein
  • Sulphonamide derivatives
    Patent number: 6713516
    Abstract: The present invention relates to the potentiation of glutamate receptor function using certain sulphonamide derivatives. It also relates to novel sulphonamide derivatives, to processes for their preparation and to pharmaceutical compositions containing them.
    Type: Grant
    Filed: December 12, 2002
    Date of Patent: March 30, 2004
    Assignee: Eli Lilly and Company
    Inventors: Macklin Brian Arnold, David Michael Bender, Andrew Hendley Fray, Winton Dennis Jones, Paul Leslie Ornstein, Richard Lee Simon, Hamideh Zarrinmayeh, Dennis Michael Zimmerman
  • Sulphonamide derivatives
    Patent number: 6693137
    Abstract: The present invention relates to the potentiation of glutamate receptor function using certain sulphonamide derivatives. It also relates to novel sulphonamide derivatives, to processes for their preparation and to pharmaceutical compositions containing them.
    Type: Grant
    Filed: January 23, 2001
    Date of Patent: February 17, 2004
    Assignee: Eli Lilly and Company
    Inventors: Macklin Brian Arnold, David Michael Bender, Buddy Eugene Cantrell, Winton Dennis Jones, Paul Leslie Ornstein, Richard Lee Simon, Edward C. R. Smith, Eric George Tromiczak, Hamideh Zarrinmayeh, Dennis Michael Zimmerman
  • Sulfonamide derivatives
    Publication number: 20030233015
    Abstract: The present invention relates to a compound of formula (Ia) or a pharmaceutically acceptable salt thereof which is useful for the treatment of conditions associated with glutamate hypofunction, such as psychiatric and neurological disorders.
    Type: Application
    Filed: October 17, 2002
    Publication date: December 18, 2003
    Inventors: James Abraham Aikins, Andrew Hendley Fray, William David Miller, Paul Leslie Ornstein, Hamideh Zarrinmayeh, Dennis Michael Zimmerman
  • Sulfonamide derivatives
    Publication number: 20030225163
    Abstract: The present invention relates to a compound of formula (I) or a pharmaceutically acceptable salt thereof which is useful for the treatment of conditions associated with glutamate hypofunction, such as psychiatric and neurological disorders.
    Type: Application
    Filed: October 17, 2002
    Publication date: December 4, 2003
    Inventors: Macklin Brian Arnold, Thomas John Bleisch, George William Cuff, Paul Leslie Ornstein, Dennis Michael Zimmerman
  • Selective iGluR5 receptor antagonists for the treatment of neurological disorders
    Publication number: 20030199546
    Abstract: The present invention provides a method of treating or preventing migraine comprising administering to a patient in need thereof an effective amount of a selective iGluR5 receptor antagonist. The present mvention further provides novel compounds functional as selective iGluR5 receptor antagonists as well as compositions and s cspng said selective iGluR5 receptor antagonists.
    Type: Application
    Filed: March 6, 2003
    Publication date: October 23, 2003
    Inventors: Sandra Ann Filla, Paul Leslie Ornstein
  • Sulphonamide derivatives
    Publication number: 20030171350
    Abstract: The present invention relates to the potentiation of glutamate receptor function using certain sulphonamide derivatives. It also relates to novel sulphonamide derivatives, to processes for their preparation and to pharmaceutical compositions containing them.
    Type: Application
    Filed: December 12, 2002
    Publication date: September 11, 2003
    Inventors: MacKlin Brian Arnold, David Michael Bender, Andrew Hendley Fray, Winton Dennis Jones, Paul Leslie Ornstein, Richard Lee Simon, Hamideh Zarrinmayeh, Dennis Michael Zimmerman
  • Amide, carbamate, and urea derivatives
    Patent number: 6617351
    Abstract: The present invention provides certain amide, carbamate and urea derivatives useful for potentiating glutamate receptor function in a mammal and therefore, useful for treating a wide variety of conditions, such as psychiatric and neurological disorders.
    Type: Grant
    Filed: January 23, 2001
    Date of Patent: September 9, 2003
    Assignee: Eli Lilly and Company
    Inventors: Macklin Brian Arnold, David Michael Bender, Thomas John Bleisch, Winton Dennis Jones, Paul Leslie Ornstein, Hamideh Zarrinmayeh, Dennis Michael Zimmerman
  • Selective iGluR5 receptor antagonists for the treatment of migraine
    Patent number: 6566370
    Abstract: The present invention provides a method of treating or preventing migraine comprising administering to a patient in need thereof an effective amount of a selective iGluR5 receptor antagonist. The present invention further provides novel compounds functional as selective iGluR5 receptor antagonists as well as compositions and formulations comprising said selective iGluR5 receptor antagonists.
    Type: Grant
    Filed: December 11, 2001
    Date of Patent: May 20, 2003
    Assignee: Eli Lilly and Company
    Inventors: David Bleakman, Sandra Ann Filla, Kirk Willis Johnson, Paul Leslie Ornstein
  • Sulfonamide derivatives
    Patent number: 6552086
    Abstract: The present invention provides certain sulfonamide derivatives useful for potentiating glutamate receptor function in a mammal and therefore, useful for treating a wide variety of conditions, such as psychiatric and neurological disorders.
    Type: Grant
    Filed: January 23, 2001
    Date of Patent: April 22, 2003
    Assignee: Eli Lilly and Company
    Inventors: Macklin Brian Arnold, Paul Leslie Ornstein, Edward C. R. Smith, Hamideh Zarrinmayeh, Dennis Michael Zimmerman
  • N-substituted sulfonamide derivatives
    Patent number: 6525099
    Abstract: The present invention provides certain N-substituted sulfonamide derivatives useful for potentiating glutamate receptor function in a mammal and therefore, useful for treating a wide variety of conditions, such as psychiatric and neurological disorders.
    Type: Grant
    Filed: January 23, 2001
    Date of Patent: February 25, 2003
    Assignee: Eli Lilly and Company
    Inventors: Macklin Brian Arnold, Winton Dennis Jones, Paul Leslie Ornstein, Hamideh Zarrinmayeh, Dennis Michael Zimmerman
  • Amidophosphate derivatives
    Patent number: 6521605
    Abstract: The present invention provides amidophosphate derivatives useful for potentiating glutamate receptor function in a mammal and therefore, useful for treating a wide variety of conditions, such as psychiatric and neurological disorders.
    Type: Grant
    Filed: January 23, 2001
    Date of Patent: February 18, 2003
    Assignee: Eli Lilly and Company
    Inventors: Macklin Brian Arnold, Paul Leslie Ornstein, Hamideh Zarrinmayeh, Dennis Michael Zimmerman
  • Sulphonamide derivatives
    Patent number: 6515026
    Abstract: The present invention relates to the potentiation of glutamate receptor function using certain sulphonamide derivatives. It also relates to novel sulphonamide derivatives, to process for their preparation and to pharmaceutical compositions containing them.
    Type: Grant
    Filed: January 18, 2002
    Date of Patent: February 4, 2003
    Assignee: Eli Lilly and Company
    Inventors: Macklin Brian Arnold, Paul Leslie Ornstein, Richard Lee Simon, Hamideh Zarrinmayeh, Dennis Michael Zimmerman
  • Sulfonamide derivatives
    Patent number: 6500865
    Abstract: The present invention provides certain sulfonamide derivatives useful for potentiating glutamate receptor function in a mammal and therefore, useful for treating a wide variety of conditions, such as psychiatric and neurological disorders.
    Type: Grant
    Filed: January 23, 2001
    Date of Patent: December 31, 2002
    Assignee: Eli Lilly and Company
    Inventors: Macklin Brian Arnold, Thomas John Bleisch, Paul Leslie Ornstein, Edward C. R. Smith, Hamideh Zarrinmayeh, Dennis Michael Zimmerman
  • Diester prodrugs of a decahydroisoquinoline-3-carboxylic acid
    Patent number: 6486175
    Abstract: The present invention relates to novel prodrug forms of 3S,4aR,6S,8aR-6-(((4-carboxy)phenyl)methyl)-1,2,3,4,4a,5,6,7,8,8a-decahydroisoquinoline-3-carboxylic acid, to pharmaceutical compositions containing the prodrug forms, and to methods of using the prodrug forms.
    Type: Grant
    Filed: December 11, 2001
    Date of Patent: November 26, 2002
    Assignee: Eli Lilly and Company
    Inventors: Thomas John Bleisch, Edward Louis Mattiuz, Paul Leslie Ornstein, Robert Eugene Stratford
  • Sulphonamide derivatives
    Publication number: 20020115864
    Abstract: The present invention relates to the potentiation of glutamate receptor function using certain sulphonamide derivatives. It also relates to novel sulphonamide derivatives, to processes for their preparation and to pharmaceutical compositions containing them.
    Type: Application
    Filed: January 18, 2002
    Publication date: August 22, 2002
    Inventors: MacKlin Brian Arnold, Paul Leslie Ornstein, Richard Lee Simon, Hamideh Zarrinmayeh, Dennis Michael Zimmerman
  • Alkenyl sulphonamide derivatives
    Patent number: 6387954
    Abstract: The present invention provides certain alkenyl sulphonamide derivatives useful for potentiating glutamate receptor function in a mammal and therefore, useful for treating a wide variety of conditions, such as psychiatric and neurological disorders.
    Type: Grant
    Filed: January 23, 2001
    Date of Patent: May 14, 2002
    Assignee: Eli Lilly and Company
    Inventors: Winton Dennis Jones, Paul Leslie Ornstein, Hamideh Zarrinmayeh, Dennis Michael Zimmerman